AvroBio Inc logo

AVRO

AvroBio Inc

$1.06

Earnings Summary

Revenue
$0Mn
Net Profits
$-29.83Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

AvroBio Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, AvroBio Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

AvroBio Inc’s net profit fell -10.91% since last year same period to $-29.83Mn in the Q1 2022. On a quarterly growth basis, AvroBio Inc has generated -5.69% fall in its net profits since last 3-months.

Net Profit Margins:

AvroBio Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, AvroBio Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AvroBio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.57
EPS Estimate Current Year
-0.57

Highlights

EPS Estimate Current Quarter:

AvroBio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.57 - a 3.39% jump from last quarter’s estimates.

EPS Estimate Current Year:

AvroBio Inc’s earning per share (EPS) estimates for the current year stand at -0.57.

Key Ratios

Key ratios of the AvroBio Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.68
Return on Assets (ROA)
-0.38
Return on Equity (ROE)
-0.7
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

AvroBio Inc’s earning per share (EPS) fell -4.62% since last year same period to -0.68 in the Q1 2022. This indicates that the AvroBio Inc has generated -4.62% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. AvroBio Inc’s return on assets (ROA) stands at -0.38.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. AvroBio Inc’s return on equity (ROE) stands at -0.7.

Dividend Per Share (DPS):

AvroBio Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.59
-0.68
-15.25%

Company Information

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

Organisation
AvroBio Inc
Employees
121
Industry
Health Technology